Translational Neuroimaging Tools for CNS Drug Discovery, Development and Treatment

Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment combines the experience of academic, clinical and industrial neuroimagers in a unique collaborative approach to provide an integrated perspective of the use of small animal and human brain imaging in developing and validating translational models and biomarkers for the study and treatment of neuropsychiatric disorders. Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment examines the translational role of neuroimaging in model development from preclinical animal models, to human experimental medicine, and finally to clinical studies. The focus of this book is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This book covers methodical issues in human and animal neuroimaging translational research as well as detailed applied examples of the use of neuroimaging in neuropsychiatric disorders and the development of drugs for their treatment. Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment appeals to non-clinical and clinical neuroscientists working in and studying neuropsychiatric disorders and their treatment as well as providing the novice researcher or researcher outside of his/her expertise the opportunity to understand the background of translational research and the use of imaging in this field.

Preface

Chapter 1: Neuroimaging Modalities: Description, Comparisons, Strengths and Weaknesses

Chapter 2: Magnetic Resonance Imaging as a Tool for Modelling Drug Treatment of CNS Disorders: Strengths and Weaknesses

Chapter 3: Small Animal Imaging as a Tool For Modelling CNS disorders: Strengths and Weaknesses

Chapter 4: Structural Magnetic Resonance Imaging as a Biomarker for the Diagnosis, Progression, and Treatment of Alzheimer’s Disease

Chapter 5: Positron Emission Tomography in Alzheimer’s disease: Diagnosis and Use as Biomarker Endpoints

Chapter 6: Rethinking the Contribution of Neuroimaging to Translation in Schizophrenia.

Chapter 7: Neuroimaging as a Translational Tool in Animal and Human Models of Schizophrenia

Chapter 8: Functional Magnetic Resonance Imaging as a Biomarker for the Diagnosis, Progression and Treatment of Autistic Spectrum Disorders

Chapter 9: Translational Neuroimaging for Drug Discovery and Development in Autism Spectrum Disorders: Guidance from Clinical Imaging and Preclinical Research

Chapter 10: Neuroimaging as a Biomarker for the Diagnosis, Progression and Treatment of Substance Abuse Disorder

Chapter 11: Translational Neuroimaging: Substance Abuse Disorders

Chapter 12: Neuroimaging Approaches to the Understanding of Depression and the Identification of Novel Antidepressants

Primary Market: Researchers in the biopharmaceutical industry and academic who actively work on CNS drug treatment studies, often found in molecular biology, pharmacology, neuroscience, and psychiatry departments drug delivery groups, as well as, researchers using animal models to study drug development and therapeutics.

Secondary Market: Graduate students, postdocs and professors at medical schools studying translational medicine.

Dr. McArthur began his professional career investigating the role of serotonin on feeding behaviour at the Clarke Institute of Psychiatry in Toronto, Canada. This interest led him to complete a PhD in the psychopharmacology of feeding behaviour and macronutrient selection with John Blundell at the University of Leeds, Leeds, UK.

In 1981 he joined Beecham Pharmaceuticals to work on adrenergic involvement in energy expenditure and obesity. In 1983 Dr McArthur began working on M1 functional agonists for the treatment of Alzheimer disease and was responsible for demonstrating the initial procognitive effects of Sabcomeline. Following the merger of Beecham with SmithKline French, Dr McArthur was appointed Business Development Executive at I.T.E.M-Labo, Paris working with Roger Porsolt in behavioural pharmacology contract research. In 1992, Robert was appointed Head of Behavioral Pharmacology at Farmitalia Carlo Erba, later Pharmacia in Milan. His lab was responsible for the preclinical behavioural pharmacology of Sabcomeline (Alzheimer’s and schizophrenia); Safinamide (epilepsy and Parkinson’s); Reboxetine (depression); Cabergoline (Parkinson’s); Nicergoline (Mild Cognitive Impairment); and Amperozide (alcoholism).

He is listed as an inventor in 19 issued patents and applications of which he is the principal inventor in 3. In 1998, Robert transferred to the Pharmacia and Upjohn Company in Kalamazoo, Michigan where as senior behavioural pharmacologist responsible, he worked on mutant mouse characterizations, the establishment of a primate unit assessing cognitive changes in monkeys (CANTAB), and development of anxiety models in marmosets. Soon after the merger of Pharmacia and Upjohn with Monsanto-Searle, Robert returned to Europe where in 2001 he founded the consulting company, McArthur and Associates GmbH in Basel.

Robert has since worked on a series of projects for both large Pharma as well as biotechs, including further primate work in Parkinson’

• Provides a background to translational research and the use of brain imaging in neuropsychiatric disorders
• Critical discussion of the potential and limitations of neuroimaging as a translational tool for identifying and validating biomarkers
• Identifies cross species neurosystems and common endpoints necessary to help accelerate CNS drug discovery and development for the treatment of neuropsychiatric disorders